Reconceptualization of immune checkpoint inhibitor-associated gastritis  

作　　者：Ying-Fang Deng Xian-Shu Cui Liang Wang 

机构地区：[1]Department of Oncology,Affiliated Hospital of Qinghai University,Xining 810000,Qinghai Province,China [2]Department of Gastrointestinal Oncology Surgery,Affiliated Hospital of Qinghai University,Xining 810000,Qinghai Province,China

出　　处：《World Journal of Gastroenterology》2024年第36期4031-4035,共5页世界胃肠病学杂志（英文版）

摘　　要：In recent years,with the extensive application of immunotherapy in clinical practice,it has achieved encouraging therapeutic effects.While enhancing clinical efficacy,however,it can also cause autoimmune damage,triggering immunerelated adverse events(irAEs).Reports of immunotherapy-induced gastritis have been increasing annually,but due to its atypical clinical symptoms,early diagnosis poses a certain challenge.Furthermore,it can lead to severe complications such as gastric bleeding,elevating the risk of adverse outcomes for solid tumor patients if immunotherapy is interrupted.Therefore,gaining a thorough understanding of the pathogenesis,clinical manifestations,diagnostic criteria,and treatment of immune-related gastritis is of utmost importance for early identification,diagnosis,and treatment.Additionally,the treatment of immune-related gastritis should be personalized according to the specific condition of each patient.For patients with grade 2-3 irAEs,restarting immune checkpoint inhibitors(ICIs)therapy may be considered when symptoms subside to grade 0-1.When restarting ICIs therapy,it is often recommended to use different types of ICIs.For grade 4 irAEs,permanent discontinuation of the medication is necessary.

关 键 词：Programmed cell death receptor-1 Programmed cell death-ligand 1 Cytotoxic T lymphocyte-associated antigen 4 Immune-related adverse events Immune-related gastritis 

分 类 号：R573.3[医药卫生—消化系统]